Penile cancer is a rare malignancy, but one with uniquely profound consequences for sexual health, body image, and intimate relationships. While advances in surgical management have improved ...

Keytruda plus platinum-based chemotherapy appeared to be safe and effective in treating penile squamous cell carcinoma. Keytruda (pembrolizumab) plus platinum-based chemotherapy was both safe and ...

A systematic review and meta-analysis compared the perioperative and oncologic outcomes of open versus minimally invasive inguinal lymphadenectomy during penile cancer surgery. A meta-analysis ...

Patients with locally advanced penile squamous cell carcinoma who responded to neoadjuvant chemotherapy followed by consolidative lymphadenectomy experienced improved long-term survival outcomes.

Although penile cancer represents less than 1% of male malignancies, it carries substantial physical and psychological burden, with a five-year survival rate near 50%. Around half of Penile squamous ...

Penile squamous cell carcinoma is a rare malignancy with limited treatment options and poor prognosis, especially in advanced stages. Because of its rarity, few studies focus on better understanding ...

In a phase 2 trial of patients with advanced penile cancer mostly refractory to platinum-based chemotherapy, avelumab treatment produced objective response in a few, but did not prolong survival ...

The median progression-free survival was 5.4 months, and the median overall survival was 9.6 months. Pembrolizumab plus platinum-based chemotherapy has demonstrated efficacy as first-line treatment ...

A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.